DeNardo GL - Search Results

1

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A, Gregg JP, O'Donnell RT, DeNardo GL. DeNardo SJ, et al. Among authors: denardo gl. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s. doi: 10.1158/1078-0432.CCR-1004-0013. Clin Cancer Res. 2005. PMID: 16203820

2

Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?

Miers L, Lamborn K, Yuan A, Richman C, Natarajan A, DeNardo S, DeNardo G. Miers L, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7158s-7163s. doi: 10.1158/1078-0432.CCR-1004-0012. Clin Cancer Res. 2005. PMID: 16203816

3

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.

O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, Meyers FJ. O'Donnell RT, et al. Among authors: denardo sj, denardo gl. Prostate. 2002 Jan 1;50(1):27-37. doi: 10.1002/pros.10029. Prostate. 2002. PMID: 11757033

4

Combined modality radioimmunotherapy. Promise and peril.

Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Burke PA, et al. Among authors: denardo sj, denardo gl. Cancer. 2002 Feb 15;94(4 Suppl):1320-31. doi: 10.1002/cncr.10303. Cancer. 2002. PMID: 11877763 Free article.

5

Rationales, evidence, and design considerations for fractionated radioimmunotherapy.

DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ. DeNardo GL, et al. Among authors: denardo sj. Cancer. 2002 Feb 15;94(4 Suppl):1332-48. doi: 10.1002/cncr.10304. Cancer. 2002. PMID: 11877764 Free article.

6

Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.

DeNardo GL, Siantar CL, DeNardo SJ. DeNardo GL, et al. Among authors: denardo sj. Cancer Biother Radiopharm. 2002 Feb;17(1):107-18. doi: 10.1089/10849780252824127. Cancer Biother Radiopharm. 2002. PMID: 11915167 Review.

7

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Burke PA, et al. Among authors: denardo sj, denardo gl. Cancer Res. 2002 Aug 1;62(15):4263-72. Cancer Res. 2002. PMID: 12154028

8

Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.

Winthrop MD, DeNardo SJ, Albrecht H, Mirick GR, Kroger LA, Lamborn KR, Venclovas C, Colvin ME, Burke PA, DeNardo GL. Winthrop MD, et al. Among authors: denardo sj, denardo gl. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3845S-53S. Clin Cancer Res. 2003. PMID: 14506182

9

Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.

DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, Mirick GR, Lamborn KR, O'Donnell RT, DeNardo GL. DeNardo SJ, et al. Among authors: denardo gl. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3854S-64S. Clin Cancer Res. 2003. PMID: 14506183

10

Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.

DeNardo GL, DeNardo SJ, Peterson JJ, Miers LA, Lam KS, Hartmann-Siantar C, Lamborn KR. DeNardo GL, et al. Among authors: denardo sj. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3865S-72S. Clin Cancer Res. 2003. PMID: 14506184

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

517 results

Search Page

Filters